A expressão da subunidade NR2B do receptor n-metil-d-aspartato (NMDA) e da indolamina-2,3-dioxigenase (IDO) no câncer de mama ductal

• Ano de defesa: 2019
• Autor(a) principal: Araújo, Márcia Cristina Colares Régis de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Neoplasias da Mama; Receptores de N-Metil-D-Aspartato
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/50321

The Brest cancer is a heterogeneous group of tumors with different clinical presentation, sensitivity to therapies, development and prognosis, being growing interest in the study of molecular markers and their signaling pathways. Inotropic glutamate N-Metil-D-Aspartate receptor (NMDA) and indoleamine-2,3-dioxygenase enzyme (IDO), this last being activated by pro-inflammatory mechanisms and related to the metabolism of tryptophan via kynurenine pathway, have being implicated in tumor proliferation. NMDA receptor is formed by seven different subunits. NMDA NR1 subunit is constitutive being present in all NMDA receptors, with variation in other receptor units. Specific blocking NMDA NR2 subunit presents fewer undesirable effects, demonstrating, in pre-clinical study, the ability to stop the growth of breast cancer cell lines. Objectivs: To check immunoexpression of NMDA receptor NR2B subunit and indoleamine-2,3-dioxygenase enzyme in samples of breast ductal cancer and metastatic site. Method: The evaluation was performed by immunohistochemistry, streptavidin-biotin technique through, with primary antibodies for NR2B subunit of the NMDA receptor and enzyme IDO 1 in 15 tissue samples from breast cancer. The marking scale set with the descriptive statistics, being divided into light between 25% to 50% markup per field; moderate between 50% to 75% markup per field; intense above 75% intensity of field marking. The markings were considered in nucleus and cytoplasm. Results: All samples showed positive immunoexpression for NMDA NR2 and IDO. Seven samples showed moderate markup for NMDA NR2 and nine samples showed intense markup for IDO1. Seven samples with weak immunolabeling for NMDA NR2 presented staging I or II. Nine patients were over 50 years of age at diagnosis, four with weak immunolabeling and five with moderate markup for NMDA NR2. Twelve samples had positive hormone receptors, among which seven with moderate immunolabeling for NMDA NR2. Eight samples had positive HER2, having five moderate immunolabeling for NMDA NR2. Two triple negative samples had low markup for NMDA NR2. Five patients underwent neoadjuvant chemotherapy, three samples after chemotherapy showed weak immunolabeling and two presented moderate NMDA NR2 labeling. Conclusion: The present study evidenced positivity for NMDA and IDO 1 immunoexpression in breast cancer patient samples, clinical studies are needed in an attempt to characterize better the NMDA receptor as a possible molecular marker in breast cancer for the future purpose as therapeutic target or prognosis.